Physicians' Academy for Cardiovascular Education

The spectrum of therapeutic options: which therapies to consider?

Listen to the podcast
10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD - Berlin, Germany

Video navigation menu

  • Atherogenic lipoproteins 01:04
  • Antithrombotic 07:17
  • Immune modulation 08:25
  • Metabolic risk and HF risk 09:22
  • Summary 10:36


Show transcript

Educational information

This lecture by Prof. Ulf Landmesser was part of the EBAC-accredited symposium "The challenge of choosing in cardiovascular risk management" held during the ESC congress 2022.


Prof. Ulf Landmesser, MD, cardiologist, Charité-Universitätsmedizin Berlin, Germany


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by unrestricted educational grants from Amgen & Novo Nordisk A/S.


This educational activity is intended for an international audience of non-US and non-UK HCPs

View the slides of this presentation

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Sorry, this content is unavailable in your country.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: